Monitoring Hepatitis and Cirrhosis by 23Na MRS/MRI

通过 23Na MRS/MRI 监测肝炎和肝硬化

基本信息

  • 批准号:
    7468554
  • 负责人:
  • 金额:
    $ 4.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-07-01 至 2010-04-30
  • 项目状态:
    已结题

项目摘要

The overall goal of this research is to develop and validate noninvasive Na magnetic resonance(MR) techniques to detect and monitor the progression of liver diseases to hepatitis and cirrhosis. Liver diseases are the eighth leading cause of death in the United States. Regardless of cause, the three major pathologic stages in many liver diseases are:1) steatosis (fataccumulation), 2) hepatitis (inflammation and necrosis), and 3) cirrhosis (fibrosis and irreversible damage). 1H MRI provides excellent methods to quantitatively image fat and water in the liver, but steatosis is a "benign" condition and does not correlate with the severity of liver disease or predict its progression. Currently, there are no reliable noninvasive methods for monitoring the progression of liver diseases. A transmembrane Na+ gradient is essential for cell survival and is disrupted by cellular damage. Because MR signal from both intra- and extracellular sodium (Nai+ and Nae+) is isochronous, either a shift reagent (SR) or the multiple-quantum-filter (MQF) technique is necessaryto discriminate between the two.An MQF Na MR signal is observed when the correlation time of Na+ is slower than its Larmar period. Because of the high macromolecule concentration inside the cells, a majority of MQF signal comes from Naj+, with only small contribution from Nae+. The three main hypotheses of this proposal are that: 1) steatosis alone does not cause any changes in the transmembrane Na+ gradient, cellular energetics, or pH; 2) hepatitis leads to an increase in total MQF23Na signal, due to both an increase in [Nai+] and a change in the intracellular environment, and no change in the MQF Nae+ signal, although an increase in extracellular space may lead to an increase in the single-quantum (SQ) Nae+ signal; and 3) development of cirrhosis/fibrosis leads to an increase in the MQF Nae+ signal due to an increase in the number of extracellular Na+ binding sites resulting from the increase in extracellular matrix components. If these hypotheses are true, then MQF 23Na MR spectroscopy and imaging can provide techniques to monitor progress of hepatitis and cirrhosis noninvasively. The hypotheses will be tested in rodent models of fatty liver, hepatitis, cirrhosis, fibrosis, and cholestasis using an in vivo Na SR, TmDOTP5". 1H and 31P MR techniques will also be used to examine the correlation between fat accumulation, bioenergetics, and Na+ and pH gradients. The results of MR experiments will be correlated with histology and blood tests for liver function. In addition, SQ and MQF23Na MRI will be implemented and optimized on a 3T clinical scanner, and the feasibility of quantitative 23Na MRI of the liver in humans will be demonstrated. The overwhelming advantage of MQF23Na MR is that it can be readily translated to human studies. Thus, the proposed 23Na MR techniques will be very helpful in both experimental studies and diagnosis of liver diseases. They may also prove useful for monitoring response to therapy, which will help tremendously in designing more effective strategies for treatment of hepatitis and cirrhosis. The proposed research will also enhance our understanding of the interrelationship between energy status and ion physiology in various stages of liver disease.
本研究的总体目标是开发和验证无创Na磁共振(MR)。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NAVIN BANSAL其他文献

NAVIN BANSAL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('NAVIN BANSAL', 18)}}的其他基金

Monitoring Hepatitis and Cirrhosis by 23Na MRS/MRI
通过 23Na MRS/MRI 监测肝炎和肝硬化
  • 批准号:
    7143227
  • 财政年份:
    2006
  • 资助金额:
    $ 4.27万
  • 项目类别:
NMR Monitoring of Temperature and Its Biological Effects
温度及其生物效应的核磁共振监测
  • 批准号:
    7459620
  • 财政年份:
    2006
  • 资助金额:
    $ 4.27万
  • 项目类别:
NMR Monitoring of Temperature and Its Biological Effects
温度及其生物效应的核磁共振监测
  • 批准号:
    7257009
  • 财政年份:
    2006
  • 资助金额:
    $ 4.27万
  • 项目类别:
NMR Monitoring of Temperature and Its Biological Effects
温度及其生物效应的核磁共振监测
  • 批准号:
    7149251
  • 财政年份:
    2006
  • 资助金额:
    $ 4.27万
  • 项目类别:
Monitoring Hepatitis and Cirrhosis by 23Na MRS/MRI
通过 23Na MRS/MRI 监测肝炎和肝硬化
  • 批准号:
    7406047
  • 财政年份:
    2006
  • 资助金额:
    $ 4.27万
  • 项目类别:
Monitoring Hepatitis and Cirrhosis by 23Na MRS/MRI
通过 23Na MRS/MRI 监测肝炎和肝硬化
  • 批准号:
    7254856
  • 财政年份:
    2006
  • 资助金额:
    $ 4.27万
  • 项目类别:
Monitoring Hepatitis and Cirrhosis by 23Na MRS/MRI
通过 23Na MRS/MRI 监测肝炎和肝硬化
  • 批准号:
    7623465
  • 财政年份:
    2006
  • 资助金额:
    $ 4.27万
  • 项目类别:
Non-invasive MR thermometry using a paramagnetic complex
使用顺磁复合体进行非侵入式 MR 测温
  • 批准号:
    6420017
  • 财政年份:
    2002
  • 资助金额:
    $ 4.27万
  • 项目类别:
MR Spectroscopy and Imaging of Sodium in Tumors
肿瘤中钠的磁共振波谱和成像
  • 批准号:
    6743790
  • 财政年份:
    2002
  • 资助金额:
    $ 4.27万
  • 项目类别:
IN VIVO 23NA NMR SPECTROSCOPY & IMAGING
体内 23NA 核磁共振波谱
  • 批准号:
    6613967
  • 财政年份:
    2002
  • 资助金额:
    $ 4.27万
  • 项目类别:

相似海外基金

Senescent hepatocytes mediate reprogramming of immune cells in acute liver failure
衰老肝细胞介导急性肝衰竭中免疫细胞的重编程
  • 批准号:
    10679938
  • 财政年份:
    2023
  • 资助金额:
    $ 4.27万
  • 项目类别:
Hepatocytes Encapsulated with mesenchymal stromal cells in alginate microbeads for the treatment of acute Liver failure in Paediatric patients (HELP)
将间充质基质细胞封装在藻酸盐微珠中的肝细胞用于治疗儿科患者的急性肝衰竭(HELP)
  • 批准号:
    MR/V038583/1
  • 财政年份:
    2022
  • 资助金额:
    $ 4.27万
  • 项目类别:
    Research Grant
Development of the innovative treatment using self iPS cell for acute liver failure
开发利用自身 iPS 细胞治疗急性肝衰竭的创新疗法
  • 批准号:
    21K08685
  • 财政年份:
    2021
  • 资助金额:
    $ 4.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH)
小儿急性肝衰竭免疫反应网络 (PALF IRN):免疫介导的病理生理学治疗 (TRIUMPH)
  • 批准号:
    10421290
  • 财政年份:
    2021
  • 资助金额:
    $ 4.27万
  • 项目类别:
Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH)
小儿急性肝衰竭免疫反应网络 (PALF IRN):免疫介导的病理生理学治疗 (TRIUMPH)
  • 批准号:
    10180251
  • 财政年份:
    2021
  • 资助金额:
    $ 4.27万
  • 项目类别:
Therapeutic effect of plasmacytoid dendritic cells transplantation for acute liver failure
浆细胞样树突状细胞移植治疗急性肝衰竭的疗效
  • 批准号:
    20K21607
  • 财政年份:
    2020
  • 资助金额:
    $ 4.27万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Macrophage Therapy for Acute Liver Failure
巨噬细胞治疗急性肝衰竭
  • 批准号:
    MR/T044802/1
  • 财政年份:
    2020
  • 资助金额:
    $ 4.27万
  • 项目类别:
    Research Grant
Investigation of an optimal environment for the proliferation of mature hepatocytes toward the rescue of acute liver failure patients
研究成熟肝细胞增殖的最佳环境以挽救急性肝衰竭患者
  • 批准号:
    19K08475
  • 财政年份:
    2019
  • 资助金额:
    $ 4.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Pediatric Acute Liver Failure (PALF) TReatment for ImmUne Mediated PathopHysiology (TRIUMPH)
小儿急性肝衰竭 (PALF) 免疫介导病理生理学治疗 (TRIUMPH)
  • 批准号:
    9789253
  • 财政年份:
    2018
  • 资助金额:
    $ 4.27万
  • 项目类别:
Cryopreservation of hiPS-derivd hepatic progenitor cells and application to acute liver failure treatment
hiPS源性肝祖细胞的冷冻保存及其在急性肝衰竭治疗中的应用
  • 批准号:
    18K08662
  • 财政年份:
    2018
  • 资助金额:
    $ 4.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了